The U.S. FDA accepted a supplemental BLA that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma after prior sorafenib therapy.
DynPort’s clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation FALLS CHURCH, Va., March 8, 2017 /PRNewswire/ — CSRA Inc. (NYSE: CSRA) today announced that a plague vaccine being developed by its subsidiary, DynPort Vaccine Company LLC (DVC), was granted Orphan Drug Designation from the U.S. Food and Drug Administration […]
Marathon Pharmaceuticals is “pausing” the launch of its Duchenne muscular dystrophy drug after U.S. lawmakers questioned why the company priced it at $89,000 a year.
Astellas Pharma plunked down $1.4 billion to acquire Ganymed Pharmaceuticals and its experimental pipeline asset IMAB362 as a first-line treatment in gastric cancer.
Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.
British drug developer GW Pharmaceuticals Plc said its experimental cannabis-derived epilepsy drug met the main goal to reduce frequency of seizures in a late-stage study.
Spurred by an infusion of $170 million, three clinical trials and a deep pipeline of cancer therapies, Blueprint Medicines has quadrupled its employee base.
INDIANAPOLIS, Nov. 24, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with metastatic squamous non-small cell lung […]
LONDON – Looking to strengthen its cardiovascular and metabolic offerings, London-based AstraZeneca (AZN) is snapping up Bay Area-based ZS Pharma (ZSPH) in a deal worth $2.7 billion in hopes of leveraging that company’s ion-trap technology treatments for hyperkalemia into a blockbuster drug. The deal, which will see AstraZeneca spend $90 per share for ZS Pharma, […]
Dublin-based Shire (SHPG) announced today that it will acquire Burlington, Mass.-based Dyax Corporation (DYAX) for about $5.9 billion. Shire will pay $37.30 per Dyax share in cash, totaling around $5.9 billion. In addition, if Dyax’s pipeline product, DX-2930 for the treatment of HAE, a rare, debilitating genetic inflammatory condition, is approved, Dyax shareholders will receive […]